Biomics Biopharma (ASX:BBM) Shares Buyback Ratio %: 0.00 (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Biomics Biopharma Shares Buyback Ratio %?

Biomics Biopharma ASX:BBM Shares Buyback Ratio % is 0.00 as of Sep. 22, 2026.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Biomics Biopharma's current shares buyback ratio was 0.00%.

Biomics Biopharma Shares Buyback Ratio % Related Terms

Biomics Biopharma Shares Buyback Ratio % Historical Data

* Premium members only.

The historical data trend for Biomics Biopharma's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomics Biopharma Shares Buyback Ratio % Chart

Biomics Biopharma Annual Data
Trend
Shares Buyback Ratio %

Biomics Biopharma Semi-Annual Data
Shares Buyback Ratio %

Biomics Biopharma Shares Buyback Ratio % Calculation

Biomics Biopharma's Shares Buyback Ratio for the fiscal year that ended in . 20 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: . 20 ) - Shares Outstanding (EOP) (A: . 20 )) / Shares Outstanding (EOP) (A: . 20 )
=( - ) /
=N/A%

Biomics Biopharma's Shares Buyback Ratio for the quarter that ended in . 20 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: . 20 ) - Shares Outstanding (EOP) (A: . 20 )) / Shares Outstanding (EOP) (A: . 20 )
=( - ) /
=N/A%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Shares Buyback Ratio % →
What does a Shares Buyback Ratio % of 0.00 mean?
Biomics Biopharma (ASX:BBM) has a Shares Buyback Ratio % of 0.00 as of Sep. 22, 2026. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Biomics Biopharma and its competitors.
Is Biomics Biopharma's Shares Buyback Ratio % too high?
Biomics Biopharma's current Shares Buyback Ratio % is 0.00.
How does Biomics Biopharma's Shares Buyback Ratio % compare to competitors?
Biomics Biopharma's Shares Buyback Ratio % of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Buyback Ratio % for a Biotechnology company?
A good Shares Buyback Ratio % depends on the Biotechnology industry context. However, Shares Buyback Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Buyback Ratio % mean?
A high Shares Buyback Ratio % can signal that a stock is expensive relative to its fundamentals. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Biomics Biopharma and its competitors. Biomics Biopharma's current Shares Buyback Ratio % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomics Biopharma stock overvalued right now?
Biomics Biopharma (ASX:BBM) has a current Shares Buyback Ratio % of 0.00. The current Shares Buyback Ratio % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Buyback Ratio % calculated?
Shares Buyback Ratio % is calculated from a company's financial statements. For Biomics Biopharma (ASX:BBM), the current Shares Buyback Ratio % is 0.00 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biomics Biopharma Business Description

Address 1 Macquarie Place, Level 36, Gateway Tower, Sydney, NSW, AUS, 2000
Biomics Biopharma Ltd is an Australian biopharmaceutical company focused on the discovery and development of RNA interference (RNAi) therapeutics based on double-stranded RNA (dsRNA) technology. The company is developing a pipeline of drug candidates targeting unmet medical needs, with a historical emphasis on antiviral and respiratory indications, including candidates for respiratory syncytial virus (RSV) and other viral infections. Its approach uses chemically modified small interfering RNA (siRNA) molecules designed to silence disease-causing genes. As a near-clinical-stage company, Biomics Biopharma does not yet generate product revenue; its activities are funded primarily through equity investment and research collaborations. The company operates from Australia and seeks to advance its candidates through preclinical and clinical development, with the goal of licensing or partnering its programs with larger pharmaceutical companies or commercialising them independently.